Could cause temporary or reversible harm; serious harm is unlikely.
Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released.
| Brand name | WEGOVY |
| Generic name | SEMAGLUTIDE |
| Active ingredient(s) | SEMAGLUTIDE |
| Distributed by / for | Cardinal Health Inc. |
| NDC | 0169-4524-14 |
| Full product label | Wegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14. |
| Recalling firm | Cardinal Health Inc. |
| Distribution | NC, SC, VA |
| Quantity | 48 Cartons |
| Recall initiated | 2025-04-09 |
| Report date | 2025-05-07 |
| Recall completed | — |
| Recall number | D-0393-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Dublin OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗